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INTRODUCTION
Hyperbilirubinemia in infants is the major leading cause of neo-
natal intensive care unit (NICU) treatment and is known to be 
an important risk factor for neonatal hearing loss. In preterm in-
fants, the clinical significance of relationship between hyperbili-
rubinemia and hearing loss is well reported [1,2]. It is also known 
that the auditory pathway is one of the most vulnerable area of 
the central nervous system for bilirubin neurotoxicity. However, 
the correlation between bilirubin levels and hearing outcome is 
still unclear. This is because bilirubin exposure cannot be accu-
rately quantified, and auditory toxicity after exposure is also quite 
variable, ranging from subtle to complete hearing loss [3]. Up to 
80% of preterm infants in NICU have a hyperbilirubinemia, 
which often present as jaundice due to bilirubin deposition. To-
tal serum bilirubin (TSB) concentration >25 mg/dL or above is 
used to determine whether phototherapy and transfusion are 
needed, but it has been reported that high levels of free uncon-
jugated bilirubin (UCB) causes neuronal toxicity through the 
blood-brain barrier [4,5]. Bilirubin is a type of neurotoxic sub-
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Objectives. Neonatal hyperbilirubinemia is considered one of the most common causative factors of hearing loss. Preterm 
infants are more vulnerable to neuronal damage caused by hyperbilirubinemia. This study aimed to evaluate the ef-
fect of hyperbilirubinemia on hearing threshold and auditory pathway in preterm infants by serial auditory brain-
stem response (ABR). In addition, we evaluate the usefulness of the unconjugated bilirubin (UCB) level compared 
with total serum bilirubin (TSB) on bilirubin-induced hearing loss. 
Methods. This study was conducted on 70 preterm infants with hyperbilirubinemia who failed universal newborn hearing 
screening by automated ABR. The diagnostic ABR was performed within 3 months after birth. Follow-up ABR was 
conducted in patients with abnormal results (30 cases). TSB and UCB concentration were compared according to 
hearing threshold by ABR. 
Results. The initial and maximal measured UCB concentration for the preterm infants of diagnostic ABR ≥40 dB nHL 
group (n=30) were statistically higher compared with ABR ≤35 dB nHL group (n=40) (P=0.031 and P=0.003, re-
spectively). In follow-up ABR examination, 13 of the ABR ≥40 dB nHL group showed complete recovery, but 17 
had no change or worsened. There was no difference in bilirubin level between the recovery group and non-recovery 
group. 
Conclusion. UCB is a better predictor of bilirubin-induced hearing loss than TSB in preterm infants as evaluated by serial 
ABR. Serial ABR testing can be a useful, noninvasive methods to evaluate early reversible bilirubin-induced hearing 
loss in preterm infants.
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stance that inhibits mitochondrial enzymes and DNA synthesis, 
which blocks excitatory signaling of the nerves. Although biliru-
bin has been reported to damage cochlear nuclei and accumula-
tion bilirubin in the auditory pathway, the mechanism of biliru-
bin-induced hearing loss has not been clearly established [6]. In 
preterm infants, precise relation between bilirubin levels and 
hearing threshold, including newborn hearing screening and di-
agnostic auditory brainstem response (ABR) is largely unknown. 
The purpose of this study is to evaluate the effect of hyperbiliru-
binemia on hearing threshold and auditory pathway in preterm 
infants by serial ABR. In addition, we evaluated the usefulness 
of the UCB concentration as compared with TSB in predicting 
bilirubin-induced hearing loss in preterm infants.
MATERIALS AND METHODS
Patients
All preterm infants, under 37 weeks gestational age, who were 
admitted to the NICU of the Severance Hospital for the treat-
ment of hyperbilirubinemia from January 2013 to December 
2017 were eligible for the study. All preterm infants were treated 
for hyperbilirubinemia according to the new 2007 guideline, 
which treatment threshold were 25% lower than previous 
guideline [7]. Of these, 85 infants were referred from universal 
newborn hearing screening (UNHS) by automated ABR (AABR) 
examination. Exclusion criteria included chromosomal abnor-
malities, TORCH (toxoplasmosis, rubella, cytomegalovirus and 
herpes simplex) infections, and cases where baseline testing 
could not be completed. So, the selected study population were 
70 infants (Fig. 1). Risk factor that might be vulnerable to biliru-
bin-induced hearing loss (Apgar score <5 at 5 minutes, clinical 
sepsis, intraventricular hemorrhage grades 3 and 4, PCO2 >60 
torr, PO2 <45 torr, and PH <7.25) were recorded for each pa-
tient during the study period. The study was approved by Insti-
tutional Review Board of the Yonsei University Severance Hos-
pital (IRB No. 4-2018-0372). Since this is a retrospective study, 
no informed consent was obtained. 
Auditory brainstem response
All NICU children in our hospital participate a two-stage AABR 
examination. The result of AABR was assumes an infant as pass-
ing the test when both ears were reacted to 35 dB nHL click 
sound stimulus. When the first test failed to pass, a retest was 
performed at intervals of 1 day or more. Infants who did not 
pass the AABR examination were referred to department of 
ENT for diagnostic ABR, considered as decision tools of hearing 
loss. The result of ABR was defined abnormal when the infant’s 
hearing threshold exceed more than 40 dB nHL in at least one 
ear. Those infants with hearing threshold ≥40 dB nHL at diag-
nostic ABR examination, performed follow-up ABR within 3 to 
6 months. ABR hearing thresholds were defined as the smallest 
stimulus sound that can be observed with a V wave, ranging 
from 25 dB nHL to 90 dB nHL at 5 dB nHL intervals. Latency 
of wave V was calculated at 90 dB nHL sound stimulation.
Bilirubin measurement
Blood samples for the measurement of TSB and UCB were per-
formed by neonatologists in NICU. Bilirubin concentration was 
examined in the first 5 postnatal days or when clinically indicat-
ed. Bilirubin measurements were performed using conventional 
laboratory techniques (standard colorimetric method). The UCB 
concentration was calculated by subtracting the direct bilirubin 
from the TSB concentration. Initial and serum peak level of bili-
rubin concentration was checked during NICU admission. 
Statistical analysis 
All statistical analyses were performed using SPSS ver. 12.0 (SPSS 
Inc., Chicago, IL, USA). The difference in parameters between 
two groups was tested using independent t-test. Spearman cor-
relation analysis was used to identify linear associations between 
two variables. The sensitivity and specificity of bilirubin level as 
   Serial auditory brainstem response (ABR) testing can be a 
useful, noninvasive methods to evaluate early reversible biliru-
bin-induced hearing loss in preterm infants. 
   Unconjugated bilirubin is a better predictor than total serum 
bilirubin in preterm infants as evaluated by serial ABR. 
   Our results highlight the importance of early detection and 
careful counselling for bilirubin-induced hearing loss of the 
preterm infants. 
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Fig. 1. Flow diagram with included and hearing characteristics of 
preterm infants in neonatal intensive care unit (NICU). AABR, auto-
mated ABR; ABR, auditory brainstem response. 
Preterm infants of
hyperbilirubinemia in NICU
85 AABR referred 15 Excluded based on exclusion criteria
70 Study population
40 ABR ≤35 dB 
nHL
30 ABR ≥40 dB 
nHL
13 Complete recovery
(43.33%)
17 Unchanged or  
worsened (56.67%)
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predictors of hearing loss were evaluated using receiver operat-
ing characteristic (ROC) curves. All data are presented as means 
and standard deviations. A P-value <0.05 was considered to re-
flect statistically significance.
RESULTS
During the study period, 85 infants who suffered from hyperbil-
irubinemia did not pass the newborn hearing screening and per-
formed diagnostic ABR. Fifteen were excluded based on pre-
defined exclusion criteria. A total 70 infants were enrolled. Flow 
diagram with included infants and hearing characteristics is giv-
en in Fig. 1. Of these 70 infants, 40 were identified as normal 
hearing (≤35 dB nHL) and 30 were identified as abnormal 
hearing (≥40 dB nHL) in the diagnostic ABR. The follow-up 
ABR performed within 3–6 months showed complete recovery 
(≤35 dB nHL) in 13 (43.33%), unchanged or worsened in 17 
(56.67%) (Fig. 1). Of these 17, eight performed additional fol-
low-up ABR within 12 months, two were recovered to normal 
hearing.
The clinical characteristics, risk factors of study population are 
given in Table 1. The mean gestational age and birthweight for 
the preterm infants were 31.4±4.4 weeks and 1,552.1±794.8 g, 
respectively. The infants of the diagnostic ABR ≤35 dB nHL and 
ABR ≥40 dB nHL group were no significant difference in gesta-
tional age (P=0.337), birth weight (P=0.572) and other risk fac-
tor (Table 1).
As shown in Table 2, preterm infants of ABR ≥40 dB nHL 
group showed significant differences in initial measured and 
maximal measured UCB concentration (P=0.031 and P=0.003, 
respectively) compared with ABR ≤35 dB nHL group. No dif-
ference was observed in the TSB concentration at initial mea-
Table 2. Comparison of bilirubin concentration between ABR ≤35 
dB nHL and ≥40 dB nHL groups
Variable Total
ABR  
≤35 dB nHL 
(n=40)
ABR  
≥40 dB nHL 
(n=30)
P-value
TSB (mg/dL)
   Initial measured 10.9±3.3 10.9±3.3 11.0±3.4 0.818
   Maximal measured 19.6±5.1 18.8±5.3 20.6±4.8 0.138
UCB (mg/dL)
   Initial measured 10.6±5.1  9.5±4.6 12.1±5.4 0.031
   Maximal measured 12.5±4.8 11.1±4.5 14.4±4.7 0.003
Values are presented as mean±standard deviation.
ABR, auditory brainstem response; TSB, total serum bilirubin; UCB, un-
conjugated bilirubin. 
Table 1. Clinical characteristics, risk factors of hyperbilirubinemic 
preterm infants <37 weeks of gestational age stratified by diagnos-
tic ABR thresholds
Characteristics Total (n=70)
ABR ≤35 dB nHL 
(n=40)
ABR ≥40 dB nHL 
(n=30)
Gestational age 
(wk)
31.4±4.4 31.0±4.5 32.0±4.2
Birth weight (g) 1,552.1±794.8 1,596.2±870.6 1,495.2±694.6
Male:female  41:29 23:17 18:12
C-sec  54 (77.1) 30 (75) 24 (80)
Apgar score <5  8 (11.4)  3 (7.5)    5 (16.7)
Sepsis  25 (35.7)  15 (37.5)   10 (33.3)
PCO2 >60  torr 4 (5.7) 2 (5)   2 (6.7)
pH <7.25   9 (12.9)   5 (12.5)   4 (13.3)
PO2 <45 torr 0 0 0
IVH >II  0 0 0
Threshold of  
diagnostic 
ABR (dB nHL)
42.3±23.3 25.6±5.8 64.5±18.9
Values are presented as mean±standard deviation or number (%).
ABR, auditory brainstem response; C-sec, caesarean section; IVH, intra-
ventricular hemorrhage.
Fig. 2. Correlation between bilirubin concentration and diagnostic auditory brainstem response (ABR) threshold. (A) Relationship between un-
conjugated bilirubin (UCB) and ABR threshold. (B) Relationship between total serum bilirubin (TSB) and ABR threshold.
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sured and maximal measured concentration (Table 2). 
Maximal concentration of TSB and diagnostic ABR thresholds 
were positive correlated but not statistically significant (R2= 
0.043, P=0.09), while maximal UCB concentration and ABR 
thresholds were statistically significant (R2=0.134, P=0.002) 
(Fig. 2).
We plotted the ROC curves to compare TSB and UCB as a 
predictor of hearing loss, defined ≥40 dB nHL in diagnostic ABR 
(Fig. 3). Area under the curves of TSB and UCB were 0.591 and 
0.705, respectively. UCB is a more sensitive and specific predic-
tor of hearing loss indicating that a UCB level of 13 mg/dL pro-
vided the best sensitivity (70%) and specificity (70%).
Infants who had a threshold of 40 dB nHL or more in diag-
nostic ABR were divided into two groups according to follow-up 
ABR results, complete recovered group (≤35 dB nHL, n=13) 
and non-recovered group (≥40 dB nHL, n=17). As shown in Ta-
ble 3, in complete recovered group, follow-up ABR threshold 
was improved by about 30 dB nHL. However, there was no sig-
nificant differences in wave V latency between two groups, and 
there was also no significant difference in bilirubin concentra-
tion (Table 3). 
DISCUSSION
Hyperbilirubinemia is one of the most common neonatal dis-
eases that requires admission in the NICU. Severe hyperbilirubi-
nemia in infants can cause a life-long debilitating disorder, 
therefore, early identification of at-risk infants during the neona-
tal period is crucial to promote the long-term outcome [8]. This 
retrospective study showed hearing results of the preterm in-
fants of hyperbilirubinemia by serial ARB and relationship be-
tween hearing status and UCB compared with TSB. TSB concen-
tration was considered to be a biochemical marker used for the 
determining the treatment, such as blood exchange transfusion 
or phototherapy. Many prospective studies have demonstrated 
association between TSB concentration and bilirubin-induced 
neuronal damage although there is substantial evidence that 
TSB concentration is a poor predictor of neuronal toxicity in-
cluding hearing loss and auditory neuropathy spectrum disorder 
(ANSD) [9-11]. Otherwise, there is a growing evidence that free 
UCB concentration is a better indicator of auditory system 
damage [1,12,13]. Free UCB, the fraction of UCB not bound to 
albumin can cross the blood-brain barrier and cause neuronal 
damages including hearing loss. Since there is no way to mea-
sure free UCB directly in our institution, we conducted this 
study with only UCB concentration. While free UCB is a more 
sensitive marker of bilirubin-induced neuronal damage, UCB is 
an another sensitive marker because TSB and UCB concentra-
tion correlate well with free UCB [12,14].
Table 3. Comparison of follow-up hearing results and bilirubin concentration between complete recovered and non-recovered group
Variable
Complete recovered (n=13) Non-recovered (n=17)
P-value
Initial Follow-up Initial Follow-up
ABR - 
   Threshold (dB nHL) 50.2±19.1 20.4±5.8 57.4±24.6 56.3±26.2
   Wave V latency (ms) 7.3±0.7  6.7±0.4 7.2±0.6 6.6±0.4
TSB (mg/dL)
   Initial measured 12.0±2.9 10.3±3.7 0.231
   Maximal measured 20.2±4.2 20.9±5.3 0.182
UCB (mg/dL)
   Initial measured 11.3±5.3 12.7±5.5 0.105
   Maximal measured 14.0±4.3 14.8±5.1 0.474
Values are presented as mean±standard deviation.
ABR, auditory brainstem response; TSB, total serum bilirubin; UCB, unconjugated bilirubin.
Variable AUC SEa)
Asymptotic 
sigb)
Asymptomatic 
lower bound
95% CI upper 
bound 
UCB 0.705 0.064 0.004 0.580 0.830
TSB 0.591 0.068 0.194 0.458 0.725
Fig. 3. Receiver operating characteristic curves predicting the risk of 
hearing loss according to bilirubin level. UCB, unconjugated biliru-
bin; TSB, total serum bilirubin; AUC, area under the curve; SE, stan-
dard error; sig, significance; CI, confidence interval. a)Under the 
nonparametric assumption. b)Null hypothesis: true area, 0.5. 
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In this study, we found that UCB concentration were signifi-
cantly increased in infants with abnormal findings in diagnostic 
ABR (≥40 dB nHL) than in TSB concentration. In addition, di-
rect correlation was found between the UCB concentration and 
the hearing threshold confirmed by ABR. Moreover, a significant 
relationship was founded between UCB level and hearing loss, 
which defined threshold ≥40 nHL in diagnostic ABR. In ROC 
curves, UCB level above 13 mg/dL provide best sensitivity and 
specificity (Fig. 3). These results of our study and several others 
suggest that UCB in preterm infants related with hyperbilirubi-
nemia is a better predictor of bilirubin-induced hearing loss as 
indicated by diagnostic ABR. The degree of hearing loss con-
firmed by diagnostic ABR is likely to be associated with UCB 
concentration. This was corroborated by Ahlfors and Parker [1] 
who reported that free UCB concentration was better predictor 
than TSB concentration of failed UNHS, as evaluated AABR in a 
retrospective study. However, compared with our study, the sub-
ject consisted of infants over 34 weeks of gestational age, not 
limited to preterm who were not confirmed hearing loss by di-
agnostic ABR. Similar to our study, in a prospective study of 
preterm infants, free UCB concentration was found to be more 
sensitive and specific predictor than TSB of abnormal ABR 
waveform change, but they did not identify the threshold change 
with follow-up ABR [12]. 
Bilirubin is a kind of neurotoxic substance that changes in en-
ergy metabolism, alteration in membrane function, decreased 
membrane potential, alteration in enzyme function, and inhibi-
tion of protein and DNA synthesis [15,16]. Although correlation 
between hearing loss and bilirubin-induced neuronal damage 
has been studied for a long time, type and sited of lesion are not 
exactly known [6]. It appears that in vitro study immature cells 
are more susceptible to bilirubin toxicity than differentiated 
cells, may also support a clinical experience that preterm infants 
are more susceptible to bilirubin-induced neuronal damage [17]. 
Bilirubin has been reported damage to cochlear nuclei and audi-
tory pathway through cochlear nerve, and the cochlear itself is 
often normal [6]. Thus, hyperbilirubinemia often causes ANSD 
[18], which defined by abnormal ABR finding in the presence of 
normal optoacoustic emissions (OAE). Rance [19] reported that 
more than 50% of children with ANSD have a history of hyper-
bilirubinemia in the neonatal period. Similarly, Saluja et al. [18] 
found that, of the infants with hyperbilirubinemia requiring ex-
change transfusion, 46% had abnormal ABR wave consistent 
with ANSD. Although hyperbilirubinemia is commonly associat-
ed with ANSD, we did not routinely perform OAE in all cases. 
Eight of the 17 infants with abnormal findings in follow-up ABR 
performed OAE, and one infant was diagnosed with ANSD. We 
will continue to follow up these patients to confirm additional 
ANSD while performing proper auditory rehabilitation. 
Congenital hearing loss should be detected within 3 months 
and early intervention such as hearing aids within 6 months is 
essential for auditory development [20]. Although UNHS has 
become widely used, maintaining sensitivity and specificity for 
appropriate screening result is still a difficult theme to consider. 
Neonatal otitis media with effusion is one of the significant 
cause of failed newborn hearing screening with reported rated 
21% [21]. It can prove to be very challenging to confirm OME 
by pneumatic otoscope and tympanometry in neonate, even by 
experienced examiner. Therefore, some infants who have recov-
ered to normal hearing in follow-up ABR are likely to have 
OME, and may have affect the outcome of our study. 
ABR is most commonly used modality to investigate biliru-
bin-induced neuronal damage in neonates and preterm infants, 
which as a direct, noninvasive assessment. Several studies have 
demonstrated reversible changes in ABR wave latency. However, 
at the infant’s periods wave I and III are not always detectable 
and therefore sequential measurements of latencies are not al-
ways possible [22]. In this study, only wave V was detectable in 
most cases, so wave V was used for analysis. In complete recov-
ered group and non-recovered group, the wave V latency tended 
to be shorter on follow-up ABR, but, there were no significant 
differences between the two groups. 
There is much interest in the potential reversibility of biliru-
bin-induced hearing loss and there is growing evidence for the 
reversibility of ABR abnormalities in animal models [12,23]. 
Mild ABR abnormalities in infants with hyperbilirubinemia may 
reverse with intervention by phototherapy and exchange blood 
transfusion. Nakamura et al. [24] found that prolonged ABR 
wave I and V latency resolved after exchange transfusion in a 
prospective study of infant with TB levels >15 mg/dL. It has 
been suggested that diagnostic ABR is sensitive to the earliest 
manifestations of neuronal damage, and treatment of hyperbili-
rubinemia by lowering TSB concentration at the time of abnor-
mal ABR may reduce neuronal damage, but there have been no 
controlled trials to confirm this finding [25]. Hearing loss caused 
by hyperbilirubinemia had a recovery rate close to 80% in nor-
mal infants [22], while it was less resilient than expected in pre-
mature infants of this study. In our study, we also observed that 
13 of 30 infants (43.33%) with abnormal finding at diagnostic 
ABR recovered to normal hearing in follow-up test within 6 to 
9 months. Of the 17 infants with abnormal finding at follow-up 
ABR, 12 were able to follow-up continuously more than 1 year. 
Additionally, two infants recovered to normal hearing within 
follow-up periods, and as a result, 15 infants (50%) with abnor-
mal results at diagnostic ABR were recovered eventually. There-
fore, we recommend that infants should be evaluated through 
sequential ABR more than 1 year even if they have abnormal 
findings on diagnostic to follow up ABR. We constantly follow 
up non-recovered group with hearing aids and proper rehabilita-
tion. Hearing loss caused by hyperbilirubinemia is found to be 
reversible but follow-up ABR test can also show permanent 
hearing loss, therefore it is necessary to accurately diagnose the 
bilirubin-induced hearing loss by sequential ABR test. In partic-
ular, it is considered necessary to provide a more careful coun-
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seling in cases of bilirubin-induced hearing loss in preterm in-
fants.
We acknowledge a few other limitations. First, we could not 
control effectively various factors related to hearing loss due to 
characteristics of premature infants and could not include normal 
control group. Secondly, we could not perform initial and follow-
up otoacoustic emission routinely, so the possibility of ANSD 
cannot be excluded. Thirdly, the retrospective character of this 
relative small study and concomitant selection bias is insufficient 
to draw conclusions. Long-term implications require additional 
investigation. 
Despite these limitations, this is the first study to report on 
evaluation of relationship between hearing status and bilirubin 
concentration through the AABR, diagnostic ABR to follow up 
ABR. Our study demonstrates that UCB concentration is a bet-
ter predictor of bilirubin-induced hearing loss than TSB in pre-
term infants as evaluated by serial ABR. Serial ABR testing can 
be a useful, noninvasive methods to evaluate early reversible 
bilirubin-induced hearing loss in preterm infants.
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